Hemogenyx Pharmaceuticals plc products
HEMO-CAR-T Immunotherapy
Hemogenyx Pharmaceuticals has constructed Chimeric Antigen Receptor (CAR) programmed T cells, termed HEMO-CAR-T, for the potential treatment of Acute Myeloid Leukemia (AML). HEMO-CAR-T is made using Hemogenyx’s proprietary humanised monoclonal antibody against a target on the surface of AML cells.
Hu-PHEC Cells
Hemogenyx Pharmaceuticals utilizes postnatal human hemogenic endothelial cells (Hu-PHEC cells), discovered by Hemogenyx Pharmaceuticals’ Co-Founder Dr Vladislav Sandler, to generate cancer-free hematopoietic stem cells (HSC) for use in transplants to treat blood cancers with superior results. A patent for Dr Sandler’s work was issued in the US in February 2020.
Advanced Hematopoietic PBMC Chimera
Originally developed for in-house testing, the company’s Advanced peripheral blood Hematopoietic Chimera (“ApbHC”) is a novel type of humanised mouse that presents several advantages over existing mouse models. It has applications for disease modelling and drug development, and potentially for biodefence.
CDX Bi-specific Antibodies for Patient Conditioning
In order to obviate the use of chemotherapeutic agents for conditioning of patients undergoing BM/HSC transplantations, Hemogenyx Pharmaceuticals developed a method of selective elimination of hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in patients using highly specific CDX antibodies. CDX antibodies belong to a class of bi-specific antibodies that redirect patients’ own immune cells to eliminate HSC. In addition, CDX antibodies show promise in efficiently eliminating malignant cells belonging to a subset of leukemia. In sum, CDX antibodies have the potential to both eliminate malignant leukemic cells and increase the efficiency of conditioning while diminishing the side effects that accompany traditional methods of patient conditioning.